quantisnow
FeedTopReportsPricing
⌘K
Live feed
14:57:27·555d
FDARegulatory
Pfizer Inc. logo

FDA Approval for HYMPAVZI issued to PFIZER INC

PFE· Pfizer Inc.
Health Care
Original source

Companies

  • PFE
    Pfizer Inc.
    Health Care

Recent analyst ratings

  • Mar 2UpdateArgus$35.00
  • Feb 25UpdateRBC Capital Mkts$25.00
  • Feb 20UpdateBarclays$25.00
  • Feb 12UpdateDaiwa Securities$27.00
  • Jan 7UpdateUBS$25.00
  • Dec 2UpdateCitigroup$26.00

Related

  • PR1d
    Pfizer Declares Second-Quarter 2026 Dividend
  • PR2d
    Pfizer Showcases Oncology Innovation and Next-Generation Pipeline at ASCO 2026
  • PR3d
    U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
  • INSIDER6d
    SEC Form 4 filed by Bourla Albert
  • INSIDER7d
    SEC Form 4 filed by Bourla Albert
  • INSIDER13d
    SEC Form 3 filed by new insider Hancock Dennis P
  • PR14d
    Pfizer Invites Shareholders to View and Listen to Webcast of April 23 Virtual 2026 Annual Meeting of Shareholders
  • PR15d
    Telix Strengthens Board with Additional Director Appointments
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022